Fingerprint
Dive into the research topics of 'Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma
Martin Hoyle, Colin Green, Jo Thompson-Coon, Zulian Liu, Karen Welch, Tiffany Moxham, Ken Stein
Research output: Contribution to journal › Article › peer-review
20
Citations
(Scopus)